AUTOIMMUNE MYOSITIS DIAGNOSIS

The role of autoantibodies in diagnosing autoimmune myositis

Diagnosis of autoimmune myositis (AIM) can be challenging due to the heterogeneity of disease presentation, overlap between subtypes, and variability in extramuscular involvement.1

 

Whilst clinical evaluation, imaging, and histopathology are core components of diagnosis, autoantibody testing has become an increasingly important component of diagnostic evaluation and subtype classification.1,2

The growing role of autoantibody testing

Identification of myositis-specific autoantibodies (MSAs) and myositis-associated autoantibodies (MAAs) has increasingly refined the diagnostic landscape in AIM.2,3 

In some patients, autoantibody testing may support:3

  • Subtype classification
  • Identification of overlap syndromes
  • Recognition of extra-muscular disease risk
  • Prognostic assessment

 

The expanding availability of serological testing continues to influence diagnostic approaches across AIM subtypes.2,3

Illustration of a charging bull decorated with antibody symbols, and a yellow glow around his horns, crashing through a room filled with blue and white ceramic pottery, with broken shelves and shattered vases scattered across the floor.

Continue exploring AIM

Learn more about the role of autoantibodies in AIM.

MSAs and MAAs

Identifying autoantibody profiles is transforming our
understanding of AIM.4,5

Find out more
How AABs drive disease

Evidence suggests that autoantibodies contribute directly to AIM
pathogenesis.2

Learn more

Abbreviations:
AAB, autoantibody; AIM, autoimmune myositis; MAA, myositis-associated autoantibody; MSA, myositis-associated autoantibody.

 

References:
1. Paik JJ, et al. Rheumatology (Oxford). 2025;64(6):3288–3302; 2. Halilu F and Christopher-Stine L. Rheumatol Immunol Res. 2022:3(1):1–10; 3. Harvey GR, et al. Curr Rheumatol Rep. 2024;27(1):5; 4. Wang G and McHugh NJ. Clin Exp Rheumatol. 2025;43(2):364–371; 5. Wu Y, et al. Front Immunol. 2024;15:1439807.